In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Novavax, Inc (NASDAQ: NVAX) was $7.34 for the day, up 2.09% from the previous closing price of $7.19. In other words, the price has increased by $2.09 from its previous closing price. On the day, 9.22 million shares were traded.
Ratios:
Our analysis of NVAX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on February 28, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On July 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.77, and their Forward P/E ratio for the next fiscal year is 20.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.04. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.95.
Stock Price History:
Over the past 52 weeks, NVAX has reached a high of $23.86, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 10.29%, while the 200-Day Moving Average is calculated to be -18.90%.
Shares Statistics:
A total of 161.96M shares are outstanding, with a floating share count of 147.60M. Insiders hold about 8.87% of the company’s shares, while institutions hold 56.77% stake in the company.
Earnings Estimates
The current rating of Novavax, Inc (NVAX) reflects the combined expertise of 5.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.24, with high estimates of $0.31 and low estimates of -$0.7.
Analysts are recommending an EPS of between $3.54 and $1.19 for the fiscal current year, implying an average EPS of $2.56. EPS for the following year is $0.31, with 6.0 analysts recommending between $2.69 and -$1.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $198M to a low estimate of $68.5M. As of the current estimate, Novavax, Inc’s year-ago sales were $415.48MFor the next quarter, 4 analysts are estimating revenue of $118M. There is a high estimate of $234M for the next quarter, whereas the lowest estimate is $35M.
A total of 5 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.26B, while the lowest revenue estimate was $941.2M, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $682.16MBased on 5 analysts’ estimates, the company’s revenue will be $566.53M in the next fiscal year. The high estimate is $996.5M and the low estimate is $324M.
